Virtual screening (VS) is a computational technique used in drug discovery to search libraries of small molecules in order to identify those structures which are most likely to bind to a drug target, typically a protein receptor or enzyme.
The global Virtual Screening for Drug Discovery market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Virtual Screening for Drug Discovery is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Virtual Screening for Drug Discovery is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Virtual Screening for Drug Discovery in Pharmaceutical Company is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Virtual Screening for Drug Discovery include MedChemExpress, TargetMol, OpenEye Scientific, Eurofins Discovery, Sygnature Discovery, Jubilant Biosys, Schr枚dinger, Inc., Cresset Group, ComputaBio, Profacgen, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Virtual Screening for Drug Discovery, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Virtual Screening for Drug Discovery.
The Virtual Screening for Drug Discovery market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Virtual Screening for Drug Discovery market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Virtual Screening for Drug Discovery companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
MedChemExpress
TargetMol
OpenEye Scientific
Eurofins Discovery
Sygnature Discovery
Jubilant Biosys
Schr枚dinger, Inc.
Cresset Group
ComputaBio
Profacgen
CD ComputaBio
Creative Biolabs
BOC Sciences
CKTTDB
HitGen
WuXi AppTec
LeadBuilder
CSNpharm
ChemNavigator
Segment by Type
Structure-based Virtual Screening (SBVS)
Ligand-based Virtual Screening (LBVS)
Hybrid Methods
Segment by Application
Pharmaceutical Company
Universities and Research Institutions
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Virtual Screening for Drug Discovery company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Virtual Screening for Drug Discovery 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Structure-based Virtual Screening (SBVS)
1.2.3 Ligand-based Virtual Screening (LBVS)
1.2.4 Hybrid Methods
1.3 麻豆原创 by Application
1.3.1 Global Virtual Screening for Drug Discovery 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pharmaceutical Company
1.3.3 Universities and Research Institutions
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Virtual Screening for Drug Discovery 麻豆原创 Perspective (2019-2030)
2.2 Global Virtual Screening for Drug Discovery Growth Trends by Region
2.2.1 Global Virtual Screening for Drug Discovery 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Virtual Screening for Drug Discovery Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Virtual Screening for Drug Discovery Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Virtual Screening for Drug Discovery 麻豆原创 Dynamics
2.3.1 Virtual Screening for Drug Discovery Industry Trends
2.3.2 Virtual Screening for Drug Discovery 麻豆原创 Drivers
2.3.3 Virtual Screening for Drug Discovery 麻豆原创 Challenges
2.3.4 Virtual Screening for Drug Discovery 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Virtual Screening for Drug Discovery Players by Revenue
3.1.1 Global Top Virtual Screening for Drug Discovery Players by Revenue (2019-2024)
3.1.2 Global Virtual Screening for Drug Discovery Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Virtual Screening for Drug Discovery 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Virtual Screening for Drug Discovery Revenue
3.4 Global Virtual Screening for Drug Discovery 麻豆原创 Concentration Ratio
3.4.1 Global Virtual Screening for Drug Discovery 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Virtual Screening for Drug Discovery Revenue in 2023
3.5 Global Key Players of Virtual Screening for Drug Discovery Head office and Area Served
3.6 Global Key Players of Virtual Screening for Drug Discovery, Product and Application
3.7 Global Key Players of Virtual Screening for Drug Discovery, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Virtual Screening for Drug Discovery Breakdown Data by Type
4.1 Global Virtual Screening for Drug Discovery Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Virtual Screening for Drug Discovery Forecasted 麻豆原创 Size by Type (2025-2030)
5 Virtual Screening for Drug Discovery Breakdown Data by Application
5.1 Global Virtual Screening for Drug Discovery Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Virtual Screening for Drug Discovery Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Virtual Screening for Drug Discovery 麻豆原创 Size (2019-2030)
6.2 North America Virtual Screening for Drug Discovery 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Virtual Screening for Drug Discovery 麻豆原创 Size by Country (2019-2024)
6.4 North America Virtual Screening for Drug Discovery 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Virtual Screening for Drug Discovery 麻豆原创 Size (2019-2030)
7.2 Europe Virtual Screening for Drug Discovery 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Virtual Screening for Drug Discovery 麻豆原创 Size by Country (2019-2024)
7.4 Europe Virtual Screening for Drug Discovery 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Virtual Screening for Drug Discovery 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Virtual Screening for Drug Discovery 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Virtual Screening for Drug Discovery 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Virtual Screening for Drug Discovery 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Virtual Screening for Drug Discovery 麻豆原创 Size (2019-2030)
9.2 Latin America Virtual Screening for Drug Discovery 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Virtual Screening for Drug Discovery 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Virtual Screening for Drug Discovery 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Virtual Screening for Drug Discovery 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Virtual Screening for Drug Discovery 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Virtual Screening for Drug Discovery 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Virtual Screening for Drug Discovery 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 MedChemExpress
11.1.1 MedChemExpress Company Details
11.1.2 MedChemExpress Business Overview
11.1.3 MedChemExpress Virtual Screening for Drug Discovery Introduction
11.1.4 MedChemExpress Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.1.5 MedChemExpress Recent Development
11.2 TargetMol
11.2.1 TargetMol Company Details
11.2.2 TargetMol Business Overview
11.2.3 TargetMol Virtual Screening for Drug Discovery Introduction
11.2.4 TargetMol Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.2.5 TargetMol Recent Development
11.3 OpenEye Scientific
11.3.1 OpenEye Scientific Company Details
11.3.2 OpenEye Scientific Business Overview
11.3.3 OpenEye Scientific Virtual Screening for Drug Discovery Introduction
11.3.4 OpenEye Scientific Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.3.5 OpenEye Scientific Recent Development
11.4 Eurofins Discovery
11.4.1 Eurofins Discovery Company Details
11.4.2 Eurofins Discovery Business Overview
11.4.3 Eurofins Discovery Virtual Screening for Drug Discovery Introduction
11.4.4 Eurofins Discovery Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.4.5 Eurofins Discovery Recent Development
11.5 Sygnature Discovery
11.5.1 Sygnature Discovery Company Details
11.5.2 Sygnature Discovery Business Overview
11.5.3 Sygnature Discovery Virtual Screening for Drug Discovery Introduction
11.5.4 Sygnature Discovery Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.5.5 Sygnature Discovery Recent Development
11.6 Jubilant Biosys
11.6.1 Jubilant Biosys Company Details
11.6.2 Jubilant Biosys Business Overview
11.6.3 Jubilant Biosys Virtual Screening for Drug Discovery Introduction
11.6.4 Jubilant Biosys Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.6.5 Jubilant Biosys Recent Development
11.7 Schr枚dinger, Inc.
11.7.1 Schr枚dinger, Inc. Company Details
11.7.2 Schr枚dinger, Inc. Business Overview
11.7.3 Schr枚dinger, Inc. Virtual Screening for Drug Discovery Introduction
11.7.4 Schr枚dinger, Inc. Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.7.5 Schr枚dinger, Inc. Recent Development
11.8 Cresset Group
11.8.1 Cresset Group Company Details
11.8.2 Cresset Group Business Overview
11.8.3 Cresset Group Virtual Screening for Drug Discovery Introduction
11.8.4 Cresset Group Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.8.5 Cresset Group Recent Development
11.9 ComputaBio
11.9.1 ComputaBio Company Details
11.9.2 ComputaBio Business Overview
11.9.3 ComputaBio Virtual Screening for Drug Discovery Introduction
11.9.4 ComputaBio Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.9.5 ComputaBio Recent Development
11.10 Profacgen
11.10.1 Profacgen Company Details
11.10.2 Profacgen Business Overview
11.10.3 Profacgen Virtual Screening for Drug Discovery Introduction
11.10.4 Profacgen Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.10.5 Profacgen Recent Development
11.11 CD ComputaBio
11.11.1 CD ComputaBio Company Details
11.11.2 CD ComputaBio Business Overview
11.11.3 CD ComputaBio Virtual Screening for Drug Discovery Introduction
11.11.4 CD ComputaBio Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.11.5 CD ComputaBio Recent Development
11.12 Creative Biolabs
11.12.1 Creative Biolabs Company Details
11.12.2 Creative Biolabs Business Overview
11.12.3 Creative Biolabs Virtual Screening for Drug Discovery Introduction
11.12.4 Creative Biolabs Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.12.5 Creative Biolabs Recent Development
11.13 BOC Sciences
11.13.1 BOC Sciences Company Details
11.13.2 BOC Sciences Business Overview
11.13.3 BOC Sciences Virtual Screening for Drug Discovery Introduction
11.13.4 BOC Sciences Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.13.5 BOC Sciences Recent Development
11.14 CKTTDB
11.14.1 CKTTDB Company Details
11.14.2 CKTTDB Business Overview
11.14.3 CKTTDB Virtual Screening for Drug Discovery Introduction
11.14.4 CKTTDB Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.14.5 CKTTDB Recent Development
11.15 HitGen
11.15.1 HitGen Company Details
11.15.2 HitGen Business Overview
11.15.3 HitGen Virtual Screening for Drug Discovery Introduction
11.15.4 HitGen Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.15.5 HitGen Recent Development
11.16 WuXi AppTec
11.16.1 WuXi AppTec Company Details
11.16.2 WuXi AppTec Business Overview
11.16.3 WuXi AppTec Virtual Screening for Drug Discovery Introduction
11.16.4 WuXi AppTec Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.16.5 WuXi AppTec Recent Development
11.17 LeadBuilder
11.17.1 LeadBuilder Company Details
11.17.2 LeadBuilder Business Overview
11.17.3 LeadBuilder Virtual Screening for Drug Discovery Introduction
11.17.4 LeadBuilder Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.17.5 LeadBuilder Recent Development
11.18 CSNpharm
11.18.1 CSNpharm Company Details
11.18.2 CSNpharm Business Overview
11.18.3 CSNpharm Virtual Screening for Drug Discovery Introduction
11.18.4 CSNpharm Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.18.5 CSNpharm Recent Development
11.19 ChemNavigator
11.19.1 ChemNavigator Company Details
11.19.2 ChemNavigator Business Overview
11.19.3 ChemNavigator Virtual Screening for Drug Discovery Introduction
11.19.4 ChemNavigator Revenue in Virtual Screening for Drug Discovery Business (2019-2024)
11.19.5 ChemNavigator Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
MedChemExpress
TargetMol
OpenEye Scientific
Eurofins Discovery
Sygnature Discovery
Jubilant Biosys
Schr枚dinger, Inc.
Cresset Group
ComputaBio
Profacgen
CD ComputaBio
Creative Biolabs
BOC Sciences
CKTTDB
HitGen
WuXi AppTec
LeadBuilder
CSNpharm
ChemNavigator
听
听
*If Applicable.
